Form 8-K · Current Report · Filed 2024-03-14
Gilead Sciences Director Kevin E. Lofton to Retire
On March 10, 2024, Kevin E. Lofton, a director of Gilead Sciences, Inc., announced his decision to retire from the Board, effective at the conclusion of his term at the Company's next annual meeting on May 8, 2024. This decision was not due to any disagreement with the Board or management.
- Filer
- Gilead Sciences Inc. GILD · NASDAQ
- Filed
- Accession
- 0001104659-24-034493
- CIK
- 0000882095
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Market reaction
Close before filing
$75.94
Next session
-3.0%
Since filing
+71.5%
Latest close
$130.21
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from GILD reporting the same item, with the next session's move:
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Never miss another GILD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.